Get started
$PCIB.OL: Successful clinical translation of fimaVacc technologyOSL:PCIB www.netfonds.no Oslo (Norway), 2 May 2019 . PCI Biotech ( OSL:PCIB ), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fima_Vacc_ Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4 T-cell responses and an improved CD8 T-cell functionality after vaccination at tolerable dose levels. The interim clinical results previously reported that fima_Vacc_ may enhance overall T-cell responses, especially to the HPV peptide, which is much less immunogenic than the KLH protein. The final data confirms these results, showing a substantial increase in number of T-cell responders to the HPV peptides already after two vaccinations and a clear enhancement in the T-cell responses compared to the control group. The important CD8 responses are also more robust with fima_Vacc_ and exhibit increased functionality compared to control. The overall clinical data cover more than 90 subjects providing clinical support of fima_Vacc_.s potential to enhance the cellular immune responses that are important for therapeutic effect of vaccines. This enhancement of cellular immune responses was seen at well tolerated fima_Vacc_ dose levels, with the tolerability of fima_Vacc_ also established across a wide range of doses. The analysis of overall T-cell responses has been done in collaboration with Oslo University Hospital, The Radium Hospital, while the analysis of CD8 T-cell responses has been done at Leiden University Medical Centre (LUMC). Per Walday, CEO of PCI Biotech, said_: “Improving immunogenicity of vaccine candidates is a main priority in the immunotherapy industry. The encouraging results of the Phase I study provide proof of concept and efficacy in terms of optimal dosing of fimaVacc in humans as well as an overall characterization of tolerability, in keeping with the target objectives of the trial and paving the way for further development in a clinical setting.”_ The study was designed as an open-label, antigen-adjuvant controlled study with the objectives to determine immune responses, safety and tolerability of fima_Vacc_ in healthy volunteers. The study was performed with two model vaccines; a large immunogenic protein (KLH) and two smaller less immunogenic peptides (HPV). More than 90 subjects are included and recruitment is now stopped.
OSL:PCIBLong
by savepiginvest
1
Photocure $PHO.OL breakout watch on strong Cysview expectationsPhotocure $PHO.OL approaching relevant resistance levels and a breakout to the upside could easily be triggered as the market cap of the company is still low. Recent Edison analysis quote: " Phenomenal US growth Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit sales increased 69% during the quarter and are up 45% for the year. The total installed base of blue light cystoscopes (both rigid and flexible) increased to 157, up 51% from 104 at the beginning of 2018." www.edisongroup.com
OSL:PHO
by savepiginvest
1
Photocure $PHO.OL stock rally ahead of Q4 report - One to watchPhotocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks. As mentioned in an earlier TradingView analysis ( ), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time. Entry at these levels should probably be done with a keen eye on risk management and new investors may want to wait for the soon to come Q4 2018 report before making a move, but the long term uptrend looks promising, and at a valuation of only 113 million USD this Norwegian microcap could go a long way yet. Quoting Pengana capital about their position in Photocure: "Photocure has a current market capitalisation of USD $130 million and we estimate 2018 revenue of USD $25 million which is small compared to the potential US market opportunity valued at $1.3 billion. The company has also had great success in selling its product in Europe, with an 80% penetration in bladder surgery procedures in Scandinavia followed by 30% in Germany." www.raskmedia.com.au
OSL:PHO
by savepiginvest
Aker Bp reached potential top for nowAker Bp have made an retracement back to fib 0.618 after a huge drop. It seems it has reached it's top for now, a lot of candles with long wicks is forming. There is also showing bearish divergence on the daily RSI. First target is at the support line price 278.6 after that we might see a bounce to 292.8 before heading to fib 0.382, price 267.2. Trade with care, have fun & make money. This is not an advice, make your own decision!
OSL:AKRBPShort
by UnknownUnicorn2034381
PGSO forming a potential Head & Shoulder pattern.CHXEUR:PGSO has been in a huge uptrend since 30th November 2017, soaring over 270% in less than 240 days. - Now it's in a downtrend, and looks to be forming a H&S formation. - It broke it's ascending trendline and also failed the recent pullback. (Marked in stapled red) - Should the price break through the 200 sma, we might see the 50 sma crossing down and generate a bearish death cross. - If the support line of the H&S formation break (red descending line), the price target should be around the 14.82 area. (Marked by yellow) To me it looks bearish, but I will remain neutral. I would go short should the H&S pattern be confirmed by a break of it's support line. As an apprentice of Technical Analysis, any constructive feedback would be greatly appreaciated. BlackCrown
P
by BlackCrown